Seeking Alpha

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports ...
Nasdaq

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions "Avidity has expanded the possibilities of what RNA therapeutics can ...
Seeking Alpha

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

SAN DIEGO, April 24, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...